Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romyelocel-L (CLT-008) in AML Induction Chemotherapy
NCT02282215Phase 2Completed
- Sponsor
- Cellerant Therapeutics
- Start
- Dec 2014
- Primary completion
- Sep 2017
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CLT-008 in neutropenia and febrile neutropenia (FN) (4 arms), sponsored by Cellerant Therapeutics. Primary endpoint: Duration of febrile episodes (fever) at 42 days. Started Dec 2014; status: completed.
02
Drugs
CLT-008
03
Conditions
neutropeniafebrile neutropenia (FN)
Beyond the preview
Go deeper on NCT02282215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282215.